Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target and the rates of infection were higher with secuk inumab than with placebo in both studies and were similar to those with etanercept.
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
- M. Lebwohl, B. Strober, A. Nirula
- Medicine, BiologyThe New England journal of medicine
- 30 September 2015
Bdalumab treatment resulted in significant clinical improvements in patients with moderate-to-severe psoriasis, and was found to be superior to placebo at week 12 with respect to a 100% reduction in PASI score (PASI 100).
Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment.
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.
Briakinumab showed higher efficacy than methotrexate in patients with moderate-to-severe psoriasis, and serious infections and cancers occurred more frequently with briakinumabs, but the differences were not significant.
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey.
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Extended exposure to 50 mg of etanercept twice weekly resulted in exposure-adjusted rates of adverse events and infections similar to those in patients receiving placebo, and improvements in physician- and patient-reported measures of psoriasis severity were observed for up to 96 weeks of continuous etanerscept therapy.